Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Therapeutic Advances in Medical OncologyOpen Access

Efficacy and safety of a novel treatment scheme of RC48-ADC plus PD-1 inhibitors in metastatic urothelial carcinoma: a multicenter real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJun LinYWYaoan WenJHJie Huang

Discussion

Loading...

Member takes

Overview

Multicenter real-world study demonstrates effective first-line therapy with manageable adverse events in metastatic urothelial carcinoma patients.

Key Points

  • Combination therapy shows high efficacy with an objective response rate of 71.4% in metastatic urothelial carcinoma.
  • Median progression-free survival reaches 10.5 months with a strong safety profile in patients treated.
  • Retrospective cohort study collects data from three medical centers between July 2021 and February 2024.
  • Study highlights the potential of RC48-ADC and PD-1 inhibitors as a promising treatment strategy in real-world settings.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/6930dc5fea1aef094cca1ccbhttps://doi.org/10.1177/17588359251395928
View Full Paper
Ask AI
Bookmark
Share